CARTITUDE-6 / EMagine (MMY3005 / EMN28) Trial

[Slide 1] CARTITUDE PROGRAM CARTITUDE-1 (n=97) Accelerated FDA Approval: 2/22/2022. ?? Cure in RRMM CARTITUDE-2 (multi-cohort) A - Cilta-cel in patients with RRMM having received 1-3 PLT, Len refractory B - Cilta-cel in patients with RRMM s/p 1 PLT AND early relapse (<12m) C - Cilta-cel in TCE patients and exposure to BCMA therapy (non-CAR) D- Cilta-cel in NDMM patients without CR after Ind/SCT/Consol (4-8 cycles) E- HR-NDMM => D-RVd + Ciltacel + DR maintenance as frontline therapy CARTITUDE-4 (n=419) CART vs. SOC triplets Full FDA Approval CARTITUDE-5 (n=650) Phase 3: TI - VRD+Rd vs. VRD+Cilta-cel (Accrued) CARTITUDE-6 (n=750) Phase 3: TE - D-VRd/ASCT vs. D-VRD+ Cilta (Accrued) a

[Slide 1] Induction Risk-adapted consolidation Maintenance MIDAS (IFM 2020-02) KRd+isatuximab Lenalidomide - 3 years Low-risk (6 cycles) MRD-neg ASCT and KRd+isatuximab Lenalidomide - 3 years (2 cycles) KRd+isatuximab MRD (6 cycles) ASCT and KRd+isatuximab (2 cycles) Isatuximab+iberdomide - 3 years High-risk MRD-pos Double ASCT Isatuximab+iberdomide - 3 years ADVANCE MRD-pos Option for ASCT Lenalidomide — ≥2 years Dara+KRd Y Dara+KRd ≥PR? MRD (4 cycles) (4 cycles) MRD-neg Lenalidomide — ≥2 years Randomization NDMM, N=308 N MRD-pos Option for ASCT Lenalidomide - ≥2 years KRd Y KRd ≥PR? MRD (4 cycles) (4 cycles) N MRD-neg Lenalidomide - ≥2 years Stop Y --- [Slide 2] Future- MASTER 2 Induction Intensification Consolidation Maintenance CD38MoAb-R Quadruplet x1 year X 3 cycles Stem cell collection Arm MRD (-) randomization MRD2 Sustained R MRD3 MRD MRD1 10 Arm B Negativity CD38MoAb-R AHCT X 1 year Quadruplet x6 cycles T-cell Redirecting T-cell MRD-SURE* Arm M MRD1 sor MRD1 AHCT therapy Redirecting C therapy Arm R MRD (+) randomization MRD1x MRD2 MRD3 Ann (Otherwise SOC R CD38MoAb-R AHCT CD38MoAb-R maintenance) X3 cycles X 1 year MRD-SURE - Treatment-free observation and MRD surveillance --- [Slide 3] CARTITUDE-6 D-VRd D-VRd Len maintenance ASCT Screening 1:1 randomization (4 cycles) (2 cycles) (Up to 2 years) Until Long-term D-VRd Day -7 to -5: Apheresis (6 cycles) Lymphodepletion Day 1: Cilta-cel Len maintenance progression follow-up infusion (Cy+Flu) (Up to 2 years) T-cell transduction and expansion